BMRN BioMarin Pharmaceuticals Inc
XNAS
57.02
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
BMRN
$57.02
—
What changed
Recent filings, trades and movesKey stats
$57.02
- 52-Week Range
- $49.26 – $70.98
- YTD
- -4.09%
- IV Rank (30D)
- 30.44
- Straddle Price
- $5.83
- P/C Vol Ratio
- 1.86
- Market Cap
- $10.9B
- Open
- $56.56
- Day Range
- $54.71 – $57.28
- Volume
- 1,022,772
- Prev Close
- $56.03
Fair Value
MODEL: NEUTRAL
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 0.72 |
| Cost of Equity (CAPM) | 8.49% (VRP-adj) |
| WACC | 7.72% |
| Volatility Risk Premium | +16.0pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +17.2% |
| DCF Horizon | 12 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $0.6B |
| Return on Equity (TTM) | -0.3% |
| Book / Price | 57.7% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 76.0% |
| FCF Margin (TTM) | 15.3% |
| Debt / Equity | 0.56 |
| Quality Score | 4/6 — high quality (12y DCF) |
| Market-Implied Growth | +5.8% (reverse-DCF on current price) |
| SMA 50 | $59.69 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $56.00 |
| Bollinger Width / SMA20 | 7.3% (drives anchor stability) |
| Net Debt | $2.8B |
| Market Cap | $11B |
Peers used for multiples: BIIB, NBIX, REGN
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
4%
20-Day Fair Value
≈ by Dec 8, 2026
$57.37
α +0.5%
rank 27%
conviction
40%
40-Day Fair Value
≈ by Jan 6, 2027
$57.68
α +1.1%
rank 26%
conviction
40%
60-Day Fair Value
≈ by Feb 4, 2027
$57.16
α +0.2%
rank 37%
conviction
4%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $136.01 | 21% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 23.0× · 3 peers |
| Peer EV/EBITDA | $23.03 | 6% | median 17.2× · 3 peers |
| Peer P/B | $90.16 | 8% | median 2.8× · 3 peers |
| Peer P/S | $90.76 | 8% | median 4.4× · 3 peers |
| Market Anchor (SMA50) | $59.69 | 41% | stability 100% (BB-width) |
| Options Expected (B-L 30d) | $55.95 | 16% | 15 strikes · skew +0.30 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $10.9B
- Employees
- 3,221
- List Date
- 1999-07-23
- CIK
- 0001048477
- Last Earnings
- Nov 2 after close · −3.1% vs ±7.8% expected
- Next Earnings
- ~Jan 11, 2027 (estimated)
- Headquarters
- Novato, CA
- Homepage
- https://www.biomarin.com
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -4.08% | -0.82% | 14.65% | -10.17% | -4.71% | -4.89% | -1.67% |
| Feb | -6.71% | -12.66% | -14.67% | -2.77% | 13.97% | 6.52% | -2.72% |
| Mar | -4.62% | -0.35% | -3.71% | 0.23% | -0.46% | -5.44% | -2.39% |
| Apr | 0.12% | 2.62% | -0.58% | -7.28% | -6.26% | -5.82% | -2.87% |
| May | -1.75% | -9.82% | -10.35% | -9.91% | -7.40% | 5.97% | -5.54% |
| Jun | 7.40% | 11.43% | -1.79% | 7.75% | -3.65% | 3.98% | 4.19% |
| Jul | -8.56% | 1.26% | 2.38% | 2.68% | 2.95% | 3.89% | 0.77% |
| Aug | 8.78% | 4.44% | 2.67% | 7.79% | 0.22% | 8.73% | 5.44% |
| Sep | -8.28% | -6.71% | -4.89% | -23.26% | -8.34% | -7.46% | -9.82% |
| Oct | 2.68% | -0.08% | -6.47% | -6.01% | -2.35% | 0.12% | -2.02% |
| Nov | 5.17% | 16.61% | 8.42% | -0.86% | 5.83% | -0.66%* | 5.75% |
| Dec | 4.56% | 0.46% | 4.33% | 1.06% | 8.00% | -- | 3.68% |
| Total | -7.11% | 2.80% | -12.79% | -36.98% | -4.57% | 3.36% | -9.21% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $56.08
SMA 50: $59.54
SMA 200: $58.45
Current: $57.05
EMA 12: $56.54
EMA 26: $57.10
MACD: -0.5510 | Signal: 0.3162
BEARISH
ADX (14): 23.15
WEAK TREND
+DI: 24.08
−DI: 30.15
Momentum Oscillators
RSI (14): 49.57
NEUTRAL
Stoch %K: 58.60
Stoch %D: 58.27
Williams %R: -32.70
Volume & Volatility
BB Upper: $58.16
BB Lower: $54.01
NEUTRAL
OBV: 15,534,622
Vol SMA 20: 2,595,013
Vol ROC: -57.06%
ATR: $1.92
True Range: $2.57
HV 20: 31.6%
HV 30: 29.2%
HV 60: 27.3%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before BMRN’s Nov 2 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL with confidence level (6/10)
Key Drivers:
- Strong technical momentum signals from MACD and RSI
- Positive news sentiment from recent headlines on Duchenne Muscular Dystrophy clinical trial pipeline and BioMarin's dwarfism study data
Primary Risks:
- Recent price action may be driven by speculative buying, potentially unsustainable in the long term
- IV premium vs HV30 indicates implied volatility richer than realized, suggesting potential for mean reversion
Investment Thesis: BioMarin (BMRN) has been experiencing a strong technical uptrend, supported by positive news sentiment and low volatility. While this could continue short-term, there are concerns about the sustainability of the price action and the potential for mean reversion in implied volatility.
Recent News Sentiment Impact: The recent headlines have contributed to a positive sentiment around BioMarin's clinical trial pipeline advancements and dwarfism study data. This has likely driven some buying pressure and supported the stock's technical momentum.
Technical Analysis
Trend Direction: Short-term (1-4 weeks) - Bullish, Medium-term (1-3 months) - Neutral, Long-term (3-12 months) - Bullish
Support/Resistance Levels:
- Upper Bollinger Band: $58.40
- Middle Line (SMA 20): $55.80
- Lower Bollinger Band: $53.20
Momentum Signals:
- RSI (14): 59.00 (neutral)
- MACD: 0.66 / Signal: 0.13 / Histogram: 0.53 (bullish)
Volume Analysis: Volume trends and institutional interest signals:
- On-Balance Volume (OBV): 20776878.88
- Volume Rate of Change: 29.02%
News & Sentiment Analysis
Recent Headlines Summary:
The recent headlines have been predominantly positive, highlighting advancements in BioMarin's clinical trial pipeline and study data on dwarfism.
Sentiment Assessment: Aggregate news sentiment is POSITIVE.
Catalyst Identification: Upcoming events include the company's continued efforts to advance its clinical trial pipeline and potential regulatory approvals.
Market Narrative: The recent headlines have likely driven buying pressure, supporting the stock's technical momentum. This narrative aligns with the short-term bullish trend direction.
Risk & Volatility Assessment
Beta Interpretation: Beta 0.47 (low volatility - stock moves less than market)
Volatility Regime: Current vs historical volatility levels:
- Historical Volatility: HV20 42.3% / HV30 44.4% / HV60 37.0%
- IV Premium vs HV30: 30.2% (positive = implied richer than realized)
Options Market Signals:
- IV Rank: 30.4% (Medium - shows if volatility is historically high/low)
- Current IV: 57.8%
- Expected Move: $3.65 (22 DTE), 7-DTE: $3.65
Market Context & Positioning
Sector Performance: Relative strength vs sector/market:
- BioMarin's performance has been stronger than the broader biotech sector and market.
Institutional Activity: Volume patterns suggesting institutional interest signals:
- Institutional buying pressure is present, with volume increasing on up days.
Correlation Analysis: How stock moves relative to market (R-squared interpretation):
- Correlation: 0.17
Key Levels & Action Items
Critical Price Levels:
- Upper Bollinger Band: $58.40
- Middle Line (SMA 20): $55.80
- Lower Bollinger Band: $53.20
Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
- SMA 50: $54.37
- EMA 12: $56.07
Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches:
- No earnings data available.
Risk Management: Stop-loss levels and position sizing considerations:
- Consider setting a stop-loss around the lower Bollinger Band ($53.20) to manage risk.
- Position sizing should be adjusted based on individual risk tolerance and market conditions.
Please note that this report provides an objective analysis of BioMarin's stock performance, technical indicators, news sentiment, and options activity. It does not include a buy or sell recommendation. The confidence level is 6/10 due to the potential risks and uncertainties surrounding the company's clinical trial pipeline and regulatory approvals.
Generated
News
All BMRN news →
Revenue topped $1 billion for first time, fueled by Amicus integration.
Earnings History
24 of 25 under expected move
Avg Expected Move
8.38%
Avg Actual Move
4.03%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-25 | After-Close | 11.44% | 5.30% | 0.46x | Within |
| 2021-04-29 | After-Close | 7.08% | 2.82% | 0.40x | Within |
| 2021-07-28 | After-Close | 7.18% | 0.28% | 0.04x | Within |
| 2021-10-27 | After-Close | 9.58% | 9.04% | 0.94x | Within |
| 2022-02-23 | After-Close | 10.66% | 6.27% | 0.59x | Within |
| 2022-04-27 | After-Close | 10.73% | 2.90% | 0.27x | Within |
| 2022-08-03 | After-Close | 8.14% | 5.18% | 0.64x | Within |
| 2022-10-26 | After-Close | 9.37% | 6.92% | 0.74x | Within |
| 2023-01-11 | After-Close | 4.00% | 2.18% | 0.55x | Within |
| 2023-02-27 | After-Close | 8.37% | 3.54% | 0.42x | Within |
| 2023-04-26 | After-Close | 8.61% | 0.59% | 0.07x | Within |
| 2023-07-31 | After-Close | 5.81% | 1.22% | 0.21x | Within |
| 2023-11-01 | After-Close | 5.54% | 5.17% | 0.93x | Within |
| 2024-02-22 | After-Close | 8.45% | 1.41% | 0.17x | Within |
| 2024-04-24 | After-Close | 7.95% | 9.90% | 1.25x | Exceeded |
| 2024-08-05 | After-Close | 8.17% | 7.95% | 0.97x | Within |
| 2024-10-29 | After-Close | 7.69% | 4.62% | 0.60x | Within |
| 2025-02-19 | After-Close | 8.69% | 4.76% | 0.55x | Within |
| 2025-05-01 | After-Close | 7.45% | 1.08% | 0.14x | Within |
| 2025-08-04 | After-Close | 10.74% | 2.69% | 0.25x | Within |
| 2025-10-27 | After-Close | 11.82% | 1.56% | 0.13x | Within |
| 2026-01-12 | After-Close | 5.03% | 4.35% | 0.86x | Within |
| 2026-05-04 | After-Close | 10.10% | 4.00% | 0.40x | Within |
| 2026-08-06 | After-Close | 9.07% | 3.82% | 0.42x | Within |
| 2026-11-02 | After-Close | 7.79% | 3.10% | 0.40x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
BMRN Options Activity & IV Rank
BMRN IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 38.9%
7-DTE IV: 41.6%
Expected Move: $5.83
7-DTE Move: $3.42
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 1,171
Put Volume: 2,184
P/C Volume: 1.865
BEARISH
Call OI: 33,555
Put OI: 10,373
P/C OI: 0.309
Total OI: 43,928
ATM Options Pricing
ATM Call: $2.33
ATM Put: $3.50
Call %: 4.1%
Put %: 6.1%
Chain Summary
Chain Volume: 3,355
Chain OI: 43,928
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 83rd percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
83%
vs own history
GEX tilt
+0.47
OI-weighted, today
Vanna tilt
+0.50
δ-sensitivity to IV
Charm tilt
-0.46
δ-decay vs time
Vanna tilt +0.50: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.46: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 34 ATM contracts, 22k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)23.0LowNov 9
IV Rank (30 DTE)30.4MediumNov 9
Straddle Price (30 DTE)$5.83Nov 9
Beta Analysis
Risk Metrics
Beta: 0.3527
Alpha: 12.06%
Correlation: 0.1364
R-Squared: 1.9%
Stock Volatility: 35.6%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own BMRN
7 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Viking Global Hedge fund Andreas Halvorsen | $435.8M | #29 of 90 | +7.9% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $118.5M | #291 of 3716 | -31.2% | 13F | |
| Citadel Hedge fund Ken Griffin | $64.2M | #565 of 6285 | -75.1% | 13F | |
| Oaktree Capital Asset manager Howard Marks | $62.4M | #19 of 130 | +14.4% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $25.9M | #585 of 3138 | -55.9% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $24.8M | #419 of 4729 | +16.4% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $15.7M | #252 of 997 | +32.9% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
BMRN Institutional Ownership (13F)
Filings for 2026-06-30 · 259 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 197,426,750 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
18 filers$113.23M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $54.48M | 48.12% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $13.19M | 11.65% | 2026-06-30 |
| 3 | IMC-Chicago, LLC Custodian | $7.06M | 6.24% | 2026-09-30 |
| 4 | Walleye Trading LLC | $6.55M | 5.79% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $6.28M | 5.54% | 2026-06-30 |
| 6 | UBS Group AG Custodian | $4.50M | 3.97% | 2026-06-30 |
| 7 | GROUP ONE TRADING LLC Custodian | $3.35M | 2.96% | 2026-06-30 |
| 8 | Stonepine Capital Management, LLC | $3.12M | 2.76% | 2026-06-30 |
| 9 | Simplex Trading, LLC Custodian | $3.03M | 2.68% | 2026-09-30 |
| 10 | Caption Management, LLC | $2.86M | 2.53% | 2026-06-30 |
| 11 | Millennium Management LLC Custodian | $2.40M | 2.12% | 2026-06-30 |
| 12 | Greenland Capital Management LP | $2.29M | 2.02% | 2026-06-30 |
| 13 | Citigroup Inc. Custodian | $1.80M | 1.59% | 2026-09-30 |
| 14 | Jefferies Financial Group Inc. | $900.00K | 0.79% | 2026-09-30 |
| 15 | Walleye Capital LLC | $812.52K | 0.72% | 2026-06-30 |
| 16 | TUDOR INVESTMENT CORP ET AL | $526.42K | 0.46% | 2026-06-30 |
| 17 | Raiffeisen Bank International AG | $45.12K | 0.04% | 2026-09-30 |
| 18 | INSPIRION WEALTH ADVISORS, LLC | $30.00K | 0.03% | 2026-09-30 |
10 filers$39.55M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $24.04M | 60.78% | 2026-06-30 |
| 2 | Caption Management, LLC | $4.01M | 10.13% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $2.87M | 7.25% | 2026-06-30 |
| 4 | IMC-Chicago, LLC Custodian | $2.54M | 6.43% | 2026-09-30 |
| 5 | Walleye Trading LLC | $2.32M | 5.86% | 2026-06-30 |
| 6 | Citigroup Inc. Custodian | $1.80M | 4.55% | 2026-09-30 |
| 7 | Simplex Trading, LLC Custodian | $852.00K | 2.15% | 2026-09-30 |
| 8 | Jane Street Group, LLC Custodian | $726.69K | 1.84% | 2026-06-30 |
| 9 | Walleye Capital LLC | $234.60K | 0.59% | 2026-06-30 |
| 10 | GROUP ONE TRADING LLC Custodian | $165.94K | 0.42% | 2026-06-30 |
BMRN Insider Trading (Form 4)
Latest: 2026-10-01Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Gregory R Friberg | EVP, Chief R&D Officer | Tax (F) | −4,086 | $60.00 | -$245.2K | EDGAR |
| 2026-09-14 | Robert M Plenge | Director | Award (A) | +6,140 | — | EDGAR | |
| 2026-09-03 | George Eric Davis | EVP, Chief Legal Officer | Sell (S) | −17,557 | $66.28 | -$1.16M | EDGAR |
| 2026-06-04 | Elizabeth M Anderson | Director | Award (A) | +7,490 | — | EDGAR | |
| 2026-06-04 | Barbara W. Bodem | Director | Award (A) | +7,490 | — | EDGAR | |
| 2026-06-04 | Ian T Clark | Director | Award (A) | +7,490 | — | EDGAR | |
| 2026-06-04 | Willard H Dere | Director | Award (A) | +7,490 | — | EDGAR | |
| 2026-06-04 | Mark J Enyedy | Director | Award (A) | +7,490 | — | EDGAR | |
| 2026-06-04 | Robert J. Hombach | Director | Award (A) | +7,490 | — | EDGAR | |
| 2026-06-04 | Maykin Ho | Director | Award (A) | +7,490 | — | EDGAR | |
| 2026-06-04 | Timothy P Walbert | Director | Award (A) | +7,490 | — | EDGAR | |
| 2026-06-04 | Athena Countouriotis | Director | Award (A) | +7,490 | — | EDGAR | |
| 2026-05-21 | Cristin Hubbard | EVP, Chief Commercial Officer | Tax (F) | −2,318 | $50.20 | -$116.4K | EDGAR |
| 2026-05-11 | Gregory R Friberg | EVP, Chief R&D Officer | Sell (S) | −3,281 | $53.85 | -$176.7K | EDGAR |
| 2026-03-19 | Alexander Hardy | Chief Executive Officer | Tax (F) | −4,252 | $56.05 | -$238.3K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
BMRN Insider Holdings
19 insiders · @ $57.05
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Alexander Hardy | Chief Executive Officer | 214,635 | $12.25M | $0 | 7 | 2026-03-19 |
| 2 | Richard A Meier | Director | 127,426 | $7.27M | -$2.72M | 39 | 2025-05-22 |
| 3 | Brian Mueller | EVP, Chief Financial Officer | 123,314 | $7.04M | -$13.92M | 82 | 2026-03-19 |
| 4 | Charles Greg Guyer | EVP, Chief Technical Officer | 84,140 | $4.80M | -$2.95M | 22 | 2026-03-19 |
| 5 | George Eric Davis | EVP, Chief Legal Officer | 61,003 | $3.48M | -$55.19M | 140 | 2026-09-03 |
| 6 | Robert J. Hombach | Director | 49,360 | $2.82M | $0 | 10 | 2026-06-04 |
| 7 | Gregory R Friberg | EVP, Chief R&D Officer | 47,732 | $2.72M | -$558.6K | 7 | 2026-10-01 |
| 8 | Willard H Dere | Director | 46,440 | $2.65M | -$547.6K | 13 | 2026-06-04 |
| 9 | Cristin Hubbard | EVP, Chief Commercial Officer | 42,472 | $2.42M | -$17.7K | 6 | 2026-05-21 |
| 10 | Elizabeth M Anderson | Director | 41,940 | $2.39M | $0 | 8 | 2026-06-04 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
BMRN Board & Officers
As of SEC filings through Oct 1, 2026Directors 12
- Richard A Meier · since Dec 14, 2006
- Willard H Dere · since Jul 15, 2016
- Robert J. Hombach · since Sep 29, 2017
- Elizabeth M Anderson · since Jul 8, 2019
- Maykin Ho · since Feb 17, 2021
- Alexander Hardy · since Dec 1, 2023
- Athena Countouriotis · since Dec 27, 2023
- Barbara W. Bodem · since Dec 27, 2023
- Mark J Enyedy · since Dec 27, 2023
- Timothy P Walbert · since Feb 24, 2025
- Ian T Clark · since Aug 1, 2025
- Robert M Plenge · since Sep 10, 2026
Officers 7
- Alexander Hardy · Chief Executive Officer · since Dec 1, 2023
- Brian Mueller · EVP, Chief Financial Officer · listed since Jun 2020
- Charles Greg Guyer · EVP, Chief Technical Officer · since May 4, 2020
- George Eric Davis · EVP, Chief Legal Officer · listed since Apr 2022
- Cristin Hubbard · EVP, Chief Commercial Officer · since May 20, 2024
- Gregory R Friberg · EVP, Chief R&D Officer · since Sep 30, 2024
- Rashmi Virendra Ramchandani · VP, Chief Accounting Officer · since Jan 20, 2026
Changes in the last 10 years (31)
| Sep 10, 2026 | Robert M Plenge became a director |
| Jan 20, 2026 | Rashmi Virendra Ramchandani became VP, Chief Accounting Officer |
| Aug 5, 2025 | The company announced the departure of Erin Burkhart as GVP, Chief Accounting Officer in an SEC filing |
| Aug 1, 2025 | Ian T Clark became a director |
| Feb 24, 2025 | Timothy P Walbert became a director |
| Sep 30, 2024 | Gregory R Friberg became EVP, Chief R&D Officer |
| Aug 16, 2024 | The company announced the departure of Henry J Fuchs as President, Worldwide R&D in an SEC filing |
| May 21, 2024 | Jean Jacques Bienaime reported in an SEC filing no longer being a director |
| May 20, 2024 | Cristin Hubbard became EVP, Chief Commercial Officer |
| Jan 11, 2024 | The company announced the departure of Jeffrey Robert Ajer as EVP, Chief Commercial Officer in an SEC filing |
| Dec 27, 2023 | Mark J Enyedy became a director |
| Dec 27, 2023 | Barbara W. Bodem became a director |
| Dec 27, 2023 | Athena Countouriotis became a director |
| Dec 12, 2023 | Jean Jacques Bienaime no longer listed as Chief Executive Officer in SEC filings |
| Dec 1, 2023 | Alexander Hardy became a director |
| Dec 1, 2023 | Alexander Hardy became Chief Executive Officer |
| May 2, 2022 | Erin Burkhart became GVP, Chief Accounting Officer |
| Apr 27, 2022 | George Eric Davis listed as EVP, Chief Legal Officer (previously EVP, General Counsel) in SEC filings |
| Jan 1, 2022 | Mark J Alles became a director |
| Oct 29, 2021 | The company announced the departure of Andrea Acosta as GVP, Chief Accounting Officer in an SEC filing |
| Mar 17, 2021 | Andrea Acosta listed as GVP, Chief Accounting Officer (previously GVP, Chief Accouning Officer) in SEC filings |
| Feb 17, 2021 | Maykin Ho became a director |
| Jul 21, 2020 | Andrea Acosta first on file as GVP, Chief Accouning Officer |
| Jun 30, 2020 | Brian Mueller listed as EVP, Chief Financial Officer (previously SVP, Acting CFO) in SEC filings |
| May 4, 2020 | Charles Greg Guyer became EVP, Chief Technical Officer |
| Feb 4, 2020 | Brian Mueller listed as SVP, Acting CFO (previously SVP, Corporate Controller) in SEC filings |
| Jul 8, 2019 | Elizabeth M Anderson became a director |
| Jun 6, 2019 | Robert Baffi listed as President, Global Mfg/Tech Ops (previously EVP, Technical Operations) in SEC filings |
| Sep 29, 2017 | Robert J. Hombach became a director |
| Feb 14, 2017 | Brian Mueller listed as SVP, Corporate Controller (previously VP, Corporate Controller) in SEC filings |
| Nov 29, 2016 | Henry J Fuchs listed as President, Worldwide R&D (previously EVP, Chief Medical Officer) in SEC filings |
Not reported recently (9)
- Elaine J Heron · Last reported as a director in an SEC filing dated Jun 4, 2024
- David E I Pyott · Last reported as a director in an SEC filing dated May 23, 2024
- Dennis Slamon · Last reported as a director in an SEC filing dated Mar 20, 2024
- V Bryan Lawlis · Last reported as a director in an SEC filing dated May 24, 2023
- Mark J Alles · Last reported as a director in an SEC filing dated May 24, 2023
- Michael G Grey · Last reported as a director in an SEC filing dated Mar 9, 2021
- Robert Baffi · Last reported as President, Global Mfg/Tech Ops in an SEC filing dated Mar 24, 2020
- Daniel K Spiegelman · Last reported as EVP, Chief Financial Officer in an SEC filing dated Jun 7, 2019
- Alan Lewis · Last reported as a director in an SEC filing dated Jun 6, 2019
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
BMRN Proposed Insider Sales (Form 144)
Latest: 2026-05-07
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Friberg Gregory R | Officer | 3,281 | $176.7K | 2026-05-07 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-03-11 | Guyer Charles Greg | Officer | 16,486 | $996.7K | 2026-03-11 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-02-26 | Friberg Gregory R | Officer | 6,326 | $381.9K | 2026-02-26 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-02-26 | Davis George Eric | Officer | 26,061 | $1.60M | 2026-02-26 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-05-20 | Burkhart Erin | Officer | 1,786 | $105.9K | 2025-05-20 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2025-05-02 | Hubbard Cristin | Officer | 273 | $17.7K | 2025-05-02 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2025-03-19 | Burkhart Erin | Officer | 1,295 | $92.6K | 2025-03-19 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2025-03-06 | Guyer Charles Greg | Officer | 7,034 | $501.4K | 2025-03-06 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-02-24 | Burkhart Erin | Officer | 1,344 | $91.9K | 2025-02-24 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2024-11-12 | Guyer Charles Greg | Officer | 5,278 | $350.3K | 2024-11-12 | Fidelity Brokerage Services LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-03
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-02 | Earnings results | EDGAR |
| 2026-10-06 | Earnings results | EDGAR |
| 2026-09-30 | Material agreement | EDGAR |
| 2026-09-15 | Other events | EDGAR |
| 2026-09-14 | Director or officer change | EDGAR |
| 2026-09-01 | Other events | EDGAR |
| 2026-08-31 | Material agreement · Regulation FD disclosure | EDGAR |
| 2026-08-18 | Material agreement · Regulation FD disclosure | EDGAR |
| 2026-08-06 | Earnings results | EDGAR |
| 2026-06-04 | Director or officer change · Shareholder vote results | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-02-26 | 0001048477-26-000004 | EDGAR |
| 2025-02-24 | 0001048477-25-000007 | EDGAR |
| 2024-02-26 | 0001048477-24-000016 | EDGAR |
| 2023-02-27 | 0001048477-23-000009 | EDGAR |
| 2022-02-25 | 0001048477-22-000012 | EDGAR |
| 2021-02-26 | 0001048477-21-000008 | EDGAR |
| 2020-02-27 | 0001048477-20-000009 | EDGAR |
| 2019-02-28 | 0001564590-19-005033 | EDGAR |
| 2018-02-26 | 0001564590-18-003114 | EDGAR |
| 2017-02-27 | 0001564590-17-002483 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-11-03 | 0001048477-26-000023 | EDGAR |
| 2026-08-06 | 0001048477-26-000016 | EDGAR |
| 2026-05-05 | 0001048477-26-000008 | EDGAR |
| 2025-10-28 | 0001048477-25-000107 | EDGAR |
| 2025-08-05 | 0001048477-25-000090 | EDGAR |
| 2025-05-02 | 0001048477-25-000051 | EDGAR |
| 2024-10-31 | 0001048477-24-000152 | EDGAR |
| 2024-08-05 | 0001048477-24-000126 | EDGAR |
| 2024-04-26 | 0001048477-24-000070 | EDGAR |
| 2023-11-02 | 0001048477-23-000044 | EDGAR |
ETF Holders
163 ETFs hold BMRN
25 shown · $2.26B total exposure · 0.28% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJH iShares Core S&P Mid-Cap ETF | iShares (BlackRock) | 0.32% | $392.5M | $121.4B | 2026-11-06 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.02% | $369.6M | — | 2026-09-30 |
| 3 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.15% | $261.5M | — | 2026-09-30 |
| 4 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.33% | $145.4M | — | 2026-09-30 |
| 5 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 1.33% | $133.2M | $10.0B | 2026-11-05 |
| 6 | VXF Vanguard Extended Market ETF | Vanguard | 0.14% | $130.8M | — | 2026-09-30 |
| 7 | FBT First Trust NYSE® Arca® Biotechnology Index Fund | First Trust | 3.40% | $101.0M | $3.0B | 2026-11-06 |
| 8 | DFSV Dimensional US Small Cap Value ETF | Dimensional | 0.31% | $84.8M | — | 2026-11-05 |
| 9 | MDY State Street® SPDR® S&P MIDCAP 400® ETF Trust | SPDR (State Street) | 0.32% | $82.9M | $25.6B | 2026-11-05 |
| 10 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.74% | $80.9M | $11.1B | 2026-11-06 |
| 11 | SPMD State Street® SPDR® Portfolio S&P 400™ Mid Cap ETF | SPDR (State Street) | 0.33% | $59.6M | $18.3B | 2026-11-05 |
| 12 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.15% | $50.2M | — | 2026-11-05 |
| 13 | IWR iShares Russell Mid-Cap ETF | iShares (BlackRock) | 0.08% | $46.1M | $56.9B | 2026-11-06 |
| 14 | IJK iShares S&P Mid-Cap 400 Growth ETF | iShares (BlackRock) | 0.37% | $37.7M | $10.2B | 2026-11-06 |
| 15 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.04% | $35.9M | — | 2026-11-05 |
| 16 | SCHM Schwab U.S. Mid-Cap ETF | Nport | 0.23% | $34.9M | — | 2026-08-31 |
| 17 | FMDE Fidelity Enhanced Mid Cap Core ETF | Fidelity | 0.40% | $34.0M | $8.6B | 2026-11-05 |
| 18 | VHT Vanguard Health Care ETF | Vanguard | 0.15% | $32.8M | — | 2026-09-30 |
| 19 | CALF Pacer US Small Cap Cash Cows 100 ETF | Nport | 0.79% | $28.9M | — | 2026-07-31 |
| 20 | IJJ iShares S&P Mid-Cap 400 Value ETF | iShares (BlackRock) | 0.28% | $23.8M | $8.6B | 2026-11-06 |
| 21 | IWD iShares Russell 1000 Value ETF | iShares (BlackRock) | 0.03% | $23.6M | $82.9B | 2026-11-06 |
| 22 | FNDA Schwab Fundamental U.S. Small Company ETF | Nport | 0.22% | $19.7M | — | 2026-08-31 |
| 23 | IVOO Vanguard S&P Mid-Cap 400 ETF | Vanguard | 0.34% | $19.4M | — | 2026-09-30 |
| 24 | DFAT Dimensional US Targeted Value ETF | Dimensional | 0.05% | $15.8M | — | 2026-11-05 |
| 25 | IWS iShares Russell Mid-Cap Value ETF | iShares (BlackRock) | 0.10% | $15.4M | $14.8B | 2026-11-06 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.09
TTM Revenue
$3.66B
TTM Net Income
$-19.11M
TTM Op. Cash Flow
$676.62M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $1.02B | $-122.83M | $-0.63 | $188.21M |
| Q2 '26 | 2026-06-30 | $989.71M | $44.76M | $0.23 | $168.11M |
| Q1 '26 | 2026-03-31 | $766.21M | $105.53M | $0.54 | $220.65M |
| Q4 '25 | 2025-12-31 | $874.57M | $-46.57M | $-0.24 | $99.64M |
| Q3 '25 | 2025-09-30 | $776.13M | $-30.74M | $-0.16 | $368.69M |
| Q2 '25 | 2025-06-30 | $825.41M | $240.53M | $1.23 | $185.27M |
| Q1 '25 | 2025-03-31 | $745.14M | $185.69M | $0.95 | $174.39M |
| Q4 '24 | 2024-12-31 | $747.31M | $124.94M | $0.65 | $185.63M |
| Q3 '24 | 2024-09-30 | $745.74M | $106.08M | $0.55 | $221.48M |
| Q2 '24 | 2024-06-30 | $712.03M | $107.17M | $0.55 | $118.76M |
| Q1 '24 | 2024-03-31 | $648.83M | $88.66M | $0.46 | $46.97M |
| Q4 '23 | 2023-12-31 | $646.21M | $20.38M | $0.10 | $27.48M |
Q3 2026 • period ending 2026-09-30 • filed 2026-11-03
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
154.22
P/B
1.76
P/S
3.27
EV/EBITDA
45.18
EV/Sales
4.05
ROE
1.2%
ROA
0.6%
Div Yield
0.00%
FCF Yield
7.69%
Debt/Equity
0.56
Current Ratio
—
Market Cap
$11.15B
as of 2026-11-09
BMRN vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| AMGN Amgen Inc | $249.0B | 26.9 | +8.2% | +41.6% | 33 |
| GILD Gilead Sciences Inc | $207.0B | — | +6.5% | +39.4% | 49 |
| VRTX Vertex Pharmaceuticals Inc | $138.7B | 35.4 | +10.5% | +21.6% | 63 |
| MRNA Moderna, Inc. Common Stock | $101.5B | — | −27.6% | +804.8% | 51 |
| REGN Regeneron Pharmaceuticals Inc | $93.6B | 20.5 | +18.6% | +19.5% | 57 |
| NTRA Natera, Inc. Common Stock | $45.1B | — | +36.6% | +39.5% | 44 |
| BIIB Biogen Inc. Common Stock | $36.7B | 110.3 | +2.3% | +45.1% | 100 |
| NBIX Neurocrine Biosciences Inc | $16.7B | 25.0 | +38.0% | +19.7% | 30 |
| BMRN BioMarin Pharmaceuticals Inc | $10.9B | — | +18.1% | −4.0% | 30 |
| Peer median | $97.5B | 26.9 | +9.3% | +39.4% | 50 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
12.05M
SI % of Float
6.24%
Days to Cover
4.90
Short Vol Ratio
32.7%
Free Float
193.05M
Float %
99.7%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-09-22